Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.39 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.39 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.39 |
| ▸ | CDK1 | P06493 | 6/20 | 0.39 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.39 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 8/20 | 0.38 |
| ▸ | GSK3B | P49841 | 8/20 | 0.38 |
| ▸ | CDK5R1 | Q15078 | 7/20 | 0.38 |
| ▸ | GSK3A | P49840 | 4/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 1/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10267990 | 0.83 | PDE3B (0.40) | PDE3BPDE3APARP1PARP10PARP11 | |
| SCHEMBL10298655 | 0.78 | LMNA (0.38) | SRCPDE3BPDE3ACCNB2CDK1 | |
| SCHEMBL15074613 | 0.78 | MB (0.45) | PDE3BPDE3AMST1RCCR1CCR5 | |
| SCHEMBL2782735 | 0.77 | GSK3B (0.40) | SRCPDE3BPDE3ACCNB2CDK1 | |
| SCHEMBL21620528 | 0.77 | CDK5 (0.38) | SRCPDE3BPDE3ACCNB2CDK1 | |
| SCHEMBL580431 | 0.77 | CDK5 (0.47) | SRCCCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL5893879 | 0.77 | CDK5 (0.44) | SRCPDE3BPDE3ACCNB2CDK1 | |
| SCHEMBL21104269 | 0.77 | CCNB2 (0.36) | SRCPDE3BPDE3ACCNB2CDK1 | |
| SCHEMBL14424566 | 0.77 | GSK3B (0.36) | SRCPDE3BPDE3ACCNB2CDK1 | |
| SCHEMBL29955850 | 0.77 | SRC (0.39) | SRCPDE3BPDE3ACCNB2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021032148-A1 | AMINOPYRAZINE COMPOUNDS AS HPK1 INHIBITOR AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2021-02-25 | — | — | WO | disclosed |
| US-20200385382-A1 | 6-AZAINDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-10 | — | — | US | disclosed |
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PRIVATE LTD (IN) | 2020-08-06 | — | — | US | disclosed |
| WO-2020012357-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | INTEGRAL BIOSCIENCES PVT. LTD. (IN) | 2020-01-16 | — | — | WO | disclosed |
| EP-3356330-B1 | BIARYL KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-11-20 | — | — | EP | disclosed |
| US-10246469-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-04-02 | — | — | US | disclosed |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2018-02-22 | — | — | US | disclosed |
| US-9139589-B2 | Heteroaryls and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | MILLENNIUM PHARM INC (US) | 2015-06-25 | — | — | US | disclosed |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | disclosed |
| EP-1664027-B1 | SUBSTITUTED 2,3-DIHYDRO-1H-ISOINDOL-1-ONE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2009-12-30 | — | — | EP | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531553-B2 | Heterocyclic compounds and methods of use | AMGEN INC. (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1664023-B1 | SUSTITUTED ISOQUINOLINE DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2008-08-13 | — | — | EP | disclosed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7390820-B2 | Substituted quinolinone derivatives and methods of use | AMGEN INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-7320992-B2 | Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use | AMGEN INC. (US) | 2008-01-22 | — | — | US | disclosed |
| US-20070185171-A1 | Compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10246469-B2 | Biaryl kinase inhibitors | AAK1, CAMKK1, CAMKK2 | SRC 148/4885PDE3B 3358/4885PDE3A 3247/4885 |
| US-20180051024-A1 | 2-OXO-IMIDAZOPYRIDINES AS REVERSIBLE BTK INHIBITORS AND USES THEREOF | BTK, SYK, LCK | SRC 14/4885PDE3B 970/4885PDE3A 1038/4885 |
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | SRC 4279/4885PDE3B 541/4885PDE3A 910/4885 |
| US-20070185171-A1 | Compounds and methods of use | VHL, PGF, PTGIS | SRC 988/4885PDE3B 189/4885PDE3A 288/4885 |
| US-20200339581-A1 | AMINO INDOLE COMPOUNDS USEFUL AS TLR INHIBITORS | TLR7, TLR1, TLR9 | SRC 1095/4885PDE3B 907/4885PDE3A 1050/4885 |
| US-20200385382-A1 | 6-AZAINDOLE COMPOUNDS | TLR7, TLR9, TLR5 | SRC 1735/4885PDE3B 322/4885PDE3A 341/4885 |
| US-20200247812-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | ACVR1, ACVRL1, ALK | SRC 880/4885PDE3B 137/4885PDE3A 202/4885 |
| US-20150175593-A1 | HETEROARYLS AND USES THEREOF | PIK3R1, PIK3R2, PIK3R3 | SRC 531/4885PDE3B 1410/4885PDE3A 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.